Santen Pharmaceutical Co., Ltd.

Novartis Ag

New York Blood Center, Inc.

Jcr Pharmaceuticals Co., Ltd.

Eisai Company, Limited

Yoichi Kawashima

Shiro Mita

Takakazu Morita

Hiroshi Suhara

Mitsuaki Kuwano

Ken-ichi Fujimura

Atsutoshi Ota

Hiroyuki Mibu

Tadashi Iso

Bernard Horowitz

Yukio Kusu

Yuko Fujita

Nobuaki Miyawaki

Richard W Shulman

Toyohiko Nishimura

Adrianne J Setton

Masayuki Oya

Hiroshi Masuda

Daniel S Kim

Jun-ichi Iwao

Hiroshi Yamada

Masato Horiuchi

Katsuhiko Nakata

Noriyoshi Yamamoto

Hiromi Matsumoto

Eishin Kato

Kiyoshi Matsuno

Katsumasa Ishihara

Junzo Matsumoto

Yuko Morikawa

Kikuko Yamanaka

Toshihiko Senda

Masayuki Date

Keiko Hirano

Takihisa Chiba

Masahiro Okamoto

Masataka Morishita

Eiji Funabashi

Koji Yoneda

Junichi Tomiyama

Nobuharu Kato

A bottomed conical hollowis formed in a tip end of the container body A formed of a thermoplastic material with a liquid filled and sealed therein simultaneously during the molding process, the hollow having an inside diameter enlarging toward the tip end, and a small-diameter instilling holeis penetrated through the bottom of the hollowfor controlling, at a set quantity, the liquid pushed out of the container body A.

Open instillation container and method of manufacturing the container

In an eye drops container, a barrel portionin the form of a flexible hollow cylinder defines a dent portionwhich can be gripped with two fingers.

Recessed part forming instillation container

For sealing a container ( ) consisting of a barrel portion ( ) and a cap portion ( ) threaded and tightened on the barrel portion, the sealing label ( ) includes a lower portion ( A) for substantially wrapping the barrel portion and an upper portion ( B) for substantially wrapping the cap portion. The sealing label includes horizontal perforations ( ) consisting of cut segments ( ) and uncut segments ( ) extending along a border between the upper portion and the lower portion; a knob portion ( ) disposed at an edge of the upper portion; and inclined perforations ( ) consisting of cut segments ( ) and uncut segments ( ) extending obliquely in the upper portion from the knob portion to the horizontal perforations.

Sealing label

An ophthalmic composition particularly in the form of eye-drops suitable for the treatment of diseases of the eye and surrounding areas. The composition contains a cyclosporin and a surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenyl ethers and polyoxyethylene alkyl ethers, or mixtures thereof.

Cyclosporin compositions

1,3-dialkylurea derivative

A sealed container stores therein liquid such as eye drops in a sealed state. For dispensing the liquid first time, the factory-sealed outlet of the liquid is to be unsealed with a needled of a liquid discharge plug fitted within a cap in association with a user's operation of the cap in a loosening or tightening direction when the liquid is first dispensed therefrom. The container includes a one-way rotation preventing mechanism provided respectively at mutually opposing portions of a liquid discharge plug prefitted with the cap and the container. This mechanism prevents rotation of the liquid discharge plug in the loosening direction of the cap while allowing rotation thereof in the screwing direction of the cap when the cap has been tightened to a predetermined screwing position immediately before the needle initiates it penetrating action into the sealed liquid outlet. Also, a cam mechanism is provided respectively at mutually opposed positions of the discharge plug and the cap for pushing the liquid discharge plug toward the liquid outlet of the container body to a predetermined screwing position in association with the loosening operation of the cap under the rotation-restricted state provided by the one-way rotation preventing mechanism.

Sealed container

Ophthalmic compositions

1,3-dialkylurea derivatives having a hydroxyl group

Amino acid derivative having N,N-dialkylaminophenyl group

1,4-(diphenlyalkyl) piperazine derivatives

This invention relates to novel aqueous ophthalmic compositions containing vitamin E or ester thereof as an active ingredient, sorbic acid or salts thereof as a preservative, and surfactant. The composition of this invention is useful for treatment of various eye diseases, especially for cataract.

Ophthalmic compositions containing vitamin E or ester thereof as an

This invention relates to the compounds of the formula [I] which are useful for the treatment of cataracts, and the synthetic intermediates of the formula [II], ##STR1## wherein R.sup.1 is hydroxy which can be protected by a hydroxy protective group;

Thiazine or thiomorpholine derivatives

This invention relates to the compounds of the formula [I] which are useful for the treatment of cataracts, and the synthetic intermediates of the formula [II], ##STR1## wherein R.sup.1 is hydroxy which can be protected by a protective group;

3-oxo-1,4-benzothiazine derivatives

A stable and soluble multi-dose ophthalmic solution is disclosed. The solution contains fibronectin, an amino acid, a sugar, and a lower alkyl p-hydroxybenzoate. A method treatment of ophthalmic wounds employing the ophthalmic solution, a process for preparing fibronectin for ophthalmic use, a method of lyophilizing an aqueous solution of fibronectin free of albumin, a method for inhibiting bacterial growth in an ophthalmic solution while preserving the cellular adhesion and wound healing activities of fibronectin, and a method of treatment of ophthalmic wounds administering a wound-healing accelerator solution are also disclosed.

Fibronectin-containing ophthalmic solution, method of preserving an

Growing community of inventors

Kyoto, Japan

Yoichi Kawashima